Cargando…
Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients
Characterization, diagnosis, and treatment of colorectal cancers (CRC) is difficult due to limited biopsy information, impracticality of repeated biopsies, and cancer biomarker fallibility. Circulating tumor DNA (ctDNA) has recently been investigated as a non-invasive way to gain representative gene...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066652/ https://www.ncbi.nlm.nih.gov/pubmed/29914973 http://dx.doi.org/10.1042/BSR20180322 |
_version_ | 1783343003503427584 |
---|---|
author | Yang, Ying-Chi Wang, Dong Jin, Lan Yao, Hong-Wei Zhang, Jing-Hui Wang, Jin Zhao, Xiao-Mu Shen, Chun-Ying Chen, Wei Wang, Xue-Liang Shi, Rong Chen, Si-Yi Zhang, Zhong-Tao |
author_facet | Yang, Ying-Chi Wang, Dong Jin, Lan Yao, Hong-Wei Zhang, Jing-Hui Wang, Jin Zhao, Xiao-Mu Shen, Chun-Ying Chen, Wei Wang, Xue-Liang Shi, Rong Chen, Si-Yi Zhang, Zhong-Tao |
author_sort | Yang, Ying-Chi |
collection | PubMed |
description | Characterization, diagnosis, and treatment of colorectal cancers (CRC) is difficult due to limited biopsy information, impracticality of repeated biopsies, and cancer biomarker fallibility. Circulating tumor DNA (ctDNA) has recently been investigated as a non-invasive way to gain representative gene mutations in tumors, in addition to monitoring disease progression and response to treatment. We analyzed ctDNA mutations and concentrations in 47 early- and late-stage CRC patients using a targetted sequencing approach using a panel that covers 50 cancer-related genes. ctDNA mutations in 37 genes were identified in 93.6% of the patients (n=47). The results showed that TP53, PIK3CA, APC, and EGFR were the most frequently mutated genes. Stage IV patients had significantly higher ctDNA concentration than Stage I patients, and increased ctDNA concentration correlated with increased tumor size. Additionally, ctDNA detection was found to be a greater predictor of disease when compared with five known commonly used tumor biomarkers. The present study supports the use of ctDNA as a liquid biopsy to gain clinical tumor information that may facilitate early diagnosis and treatment and improve CRC patient prognosis. |
format | Online Article Text |
id | pubmed-6066652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60666522018-08-10 Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients Yang, Ying-Chi Wang, Dong Jin, Lan Yao, Hong-Wei Zhang, Jing-Hui Wang, Jin Zhao, Xiao-Mu Shen, Chun-Ying Chen, Wei Wang, Xue-Liang Shi, Rong Chen, Si-Yi Zhang, Zhong-Tao Biosci Rep Research Articles Characterization, diagnosis, and treatment of colorectal cancers (CRC) is difficult due to limited biopsy information, impracticality of repeated biopsies, and cancer biomarker fallibility. Circulating tumor DNA (ctDNA) has recently been investigated as a non-invasive way to gain representative gene mutations in tumors, in addition to monitoring disease progression and response to treatment. We analyzed ctDNA mutations and concentrations in 47 early- and late-stage CRC patients using a targetted sequencing approach using a panel that covers 50 cancer-related genes. ctDNA mutations in 37 genes were identified in 93.6% of the patients (n=47). The results showed that TP53, PIK3CA, APC, and EGFR were the most frequently mutated genes. Stage IV patients had significantly higher ctDNA concentration than Stage I patients, and increased ctDNA concentration correlated with increased tumor size. Additionally, ctDNA detection was found to be a greater predictor of disease when compared with five known commonly used tumor biomarkers. The present study supports the use of ctDNA as a liquid biopsy to gain clinical tumor information that may facilitate early diagnosis and treatment and improve CRC patient prognosis. Portland Press Ltd. 2018-07-31 /pmc/articles/PMC6066652/ /pubmed/29914973 http://dx.doi.org/10.1042/BSR20180322 Text en © 2018 The Author(s). http://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (http://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Articles Yang, Ying-Chi Wang, Dong Jin, Lan Yao, Hong-Wei Zhang, Jing-Hui Wang, Jin Zhao, Xiao-Mu Shen, Chun-Ying Chen, Wei Wang, Xue-Liang Shi, Rong Chen, Si-Yi Zhang, Zhong-Tao Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients |
title | Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients |
title_full | Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients |
title_fullStr | Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients |
title_full_unstemmed | Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients |
title_short | Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients |
title_sort | circulating tumor dna detectable in early- and late-stage colorectal cancer patients |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066652/ https://www.ncbi.nlm.nih.gov/pubmed/29914973 http://dx.doi.org/10.1042/BSR20180322 |
work_keys_str_mv | AT yangyingchi circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients AT wangdong circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients AT jinlan circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients AT yaohongwei circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients AT zhangjinghui circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients AT wangjin circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients AT zhaoxiaomu circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients AT shenchunying circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients AT chenwei circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients AT wangxueliang circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients AT shirong circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients AT chensiyi circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients AT zhangzhongtao circulatingtumordnadetectableinearlyandlatestagecolorectalcancerpatients |